Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 9/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6423584 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAAMAPTPDE4A | |
| SCHEMBL16865878 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAAMAPTPDE4A | |
| SCHEMBL7099805 | 1.00 | ALDH1A1 (0.50) | ALDH1A1KDM4EGAAMAPTPDE4A | |
| SCHEMBL623386 | 0.91 | ALDH1A1 (0.48) | ALDH1A1KDM4EGAAMAPTPDE4A | |
| SCHEMBL14032377 | 0.89 | ACHE (0.51) | ALDH1A1KDM4EGAAMAPTL3MBTL1 | |
| SCHEMBL11982806 | 0.89 | ALDH1A1 (0.47) | ALDH1A1KDM4EGAAMAPTPDE4A | |
| SCHEMBL11982739 | 0.89 | ALDH1A1 (0.47) | ALDH1A1KDM4EGAAMAPTPDE4A | |
| SCHEMBL16865876 | 0.89 | ALDH1A1 (0.41) | ALDH1A1KDM4EGAAMAPTPDE4A | |
| Hydrochloric Acid SCHEMBL5117534 | 0.87 | ACHE (0.50) | ALDH1A1KDM4EGAAMAPTL3MBTL1 | |
| SCHEMBL24437403 | 0.87 | ALDH1A1 (0.46) | ALDH1A1KDM4EGAAMAPTPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434689-B2 | Processes for the preparation of isoindole compounds and isotopologues thereof | CELGENE CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150183739-A1 | PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF | AMGEN INC. | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183739-A1 | PROCESSES FOR THE PREPARATION OF ISOINDOLE COMPOUNDS AND ISOTOPOLOGUES THEREOF | HPD, DHPS, IDH2 | ALDH1A1 1488/4885KDM4E 2320/4885GAA 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.